- Home
- DTIL
as 04-24-2025 12:35pm EST
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is also unique in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | DURHAM |
| Market Cap: | 43.3M | IPO Year: | 2019 |
| Target Price: | $37.67 | AVG Volume (30 days): | 207.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 1.04 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.61 - $13.44 | Next Earning Date: | 05-12-2025 |
| Revenue: | $68,696,000 | Revenue Growth: | 40.98% |
| Revenue Growth (this year): | -67.38% | Revenue Growth (next year): | 30.20% |
Stock Insider Trading Activity of Precision BioSciences Inc. (DTIL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Buehler Kevin | DTIL | Director | Mar 26 '25 | Buy | $4.67 | 4,523 | $21,122.41 | 13,235 | |
| Brown Melinda | DTIL | Director | Mar 26 '25 | Buy | $4.75 | 1,839 | $8,735.25 | 9,057 | |
| Germano Geno J | DTIL | Director | Mar 25 '25 | Buy | $5.30 | 3,250 | $17,225.00 | 11,057 | |
| Amoroso Michael | DTIL | President and CEO | Mar 21 '25 | Sell | $5.56 | 964 | $5,359.84 | 109,540 | |
| Scimeca Dario | DTIL | General Counsel and Secretary | Mar 3 '25 | Sell | $4.91 | 272 | $1,335.52 | 25,000 | |
| SMITH J. JEFFERSON | DTIL | Chief Research Officer | Mar 3 '25 | Sell | $4.91 | 154 | $756.14 | 87,805 |
Latest Precision BioSciences Inc. News
DTIL Breaking Stock News: Dive into DTIL Ticker-Specific Updates for Smart Investing
Zacks
8 days ago
DTIL Gets FDA's Fast Track Tag for Hepatitis B Gene Therapy, Stock Up
MT Newswires
9 days ago
Precision BioSciences Gets FDA Fast Track Label for PBGENE-HBV
Business Wire
9 days ago
Precision BioSciences Receives U.S. FDA Fast Track Designation for PBGENE-HBV, a First-In-Class Gene Editing Therapy Designed to Eliminate the Root Cause of Chronic Hepatitis B
TipRanks
23 days ago
Biotech stocks slide as Marks resignation seen being negative for sector
Business Wire
23 days ago
Precision BioSciences to Participate in the 24th Annual Needham Virtual Healthcare Conference
Business Wire
a month ago
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2024 Results on March 26, 2025
Business Wire
a month ago
Precision BioSciences Presents Preclinical Safety and Efficacy Data Supporting Repeat Dosing of PBGENE-HBV With a Goal of Curing Chronic Hepatitis B at the Global Hepatitis Summit 2025
Business Wire
a month ago
Precision BioSciences Presents Preclinical Efficacy and Durability Data on PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy (DMD) at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference
Compare DTIL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DTIL Precision BioSciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.